- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Global Ovarian Cancer Market "Set to Reach $6.7 BN by 2028"
The ovarian cancer market was valued at $1.8bn in 2018 across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), and it is expected to grow to $6.7bn in the following 10 years, with a compound annual growth rate of 14.4%, according to GlobalData. GlobalData’s latest report, Ovarian Cancer: Opportunity Analysis and Forecasts to 2028,1 states that the main drivers of growth will be the adoption of maintenance therapy across the major markets, poly ADP-ribose polymerase (PARP) inhibitor uptake in the first-line setting, the launch of new pipeline agents, and increased screening rates for genetic markers. In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market. By 2028, another major revenue contributor will be new drug classes - notably, immune checkpoint inhibitors, with five expected to enter the market bringing combined forecasted revenues of around $1.4bn. A major barrier for growth in the ovarian cancer market, however, will be the emerging use of biosimilars and generics for some key marketed products, namely Lynparza and angiogenesis inhibitor Avastin. 1. https://bit.ly/2PA1ItB
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
